Cyclerion Therapeutics (CYCN) Competitors $3.20 +0.14 (+4.40%) Closing price 03:59 PM EasternExtended Trading$3.25 +0.05 (+1.44%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. FBRX, PLUR, RNTX, ATHE, RNXT, ATRA, PRLD, XLO, SCYX, and ACRVShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Forte Biosciences (FBRX), Pluri (PLUR), Rein Therapeutics (RNTX), Alterity Therapeutics (ATHE), RenovoRx (RNXT), Atara Biotherapeutics (ATRA), Prelude Therapeutics (PRLD), Xilio Therapeutics (XLO), SCYNEXIS (SCYX), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Forte Biosciences Pluri Rein Therapeutics Alterity Therapeutics RenovoRx Atara Biotherapeutics Prelude Therapeutics Xilio Therapeutics SCYNEXIS Acrivon Therapeutics Cyclerion Therapeutics (NASDAQ:CYCN) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations. Do institutionals & insiders have more ownership in CYCN or FBRX? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to CYCN or FBRX? In the previous week, Forte Biosciences had 4 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 4 mentions for Forte Biosciences and 0 mentions for Cyclerion Therapeutics. Forte Biosciences' average media sentiment score of 0.08 beat Cyclerion Therapeutics' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Cyclerion Therapeutics Neutral Forte Biosciences Neutral Is CYCN or FBRX more profitable? Cyclerion Therapeutics' return on equity of -55.32% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -55.32% -48.35% Forte Biosciences N/A -151.43%-118.92% Which has better valuation & earnings, CYCN or FBRX? Cyclerion Therapeutics has higher revenue and earnings than Forte Biosciences. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2.08M4.94-$5.26M-$1.16-2.76Forte BiosciencesN/AN/A-$31.48M-$16.29-0.47 Does the MarketBeat Community prefer CYCN or FBRX? Cyclerion Therapeutics received 3 more outperform votes than Forte Biosciences when rated by MarketBeat users. However, 60.78% of users gave Forte Biosciences an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote. CompanyUnderperformOutperformCyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Forte BiosciencesOutperform Votes3160.78% Underperform Votes2039.22% Which has more volatility and risk, CYCN or FBRX? Cyclerion Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Do analysts recommend CYCN or FBRX? Forte Biosciences has a consensus price target of $32.50, indicating a potential upside of 326.51%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryForte Biosciences beats Cyclerion Therapeutics on 9 of the 16 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.48M$6.50B$5.34B$8.42BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-2.819.1526.8519.72Price / Sales4.94252.36387.23121.26Price / CashN/A65.8538.2534.62Price / Book0.696.456.774.51Net Income-$5.26M$144.21M$3.23B$248.32M7 Day Performance9.76%2.38%1.81%0.60%1 Month Performance7.19%4.50%10.93%13.18%1 Year Performance18.27%-2.75%17.15%7.39% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics0.8264 of 5 stars$3.21+4.4%N/A+18.1%$10.48M$2.08M-2.8130Gap UpFBRXForte Biosciences2.6387 of 5 stars$6.28-1.6%$32.50+417.5%+30,134.7%$41.34MN/A-0.395News CoverageEarnings ReportAnalyst DowngradeGap UpPLURPluri0.4157 of 5 stars$5.32-7.6%N/A-25.8%$41.31M$678,000.00-0.95150Gap UpHigh Trading VolumeRNTXRein TherapeuticsN/A$1.80+2.3%N/AN/A$39.59MN/A-0.589Earnings ReportHigh Trading VolumeATHEAlterity Therapeutics1.967 of 5 stars$4.39-8.5%$12.00+173.3%+104.5%$38.93MN/A0.0010Gap UpRNXTRenovoRx2.6644 of 5 stars$1.06flat$7.00+560.4%-10.9%$38.75M$43,000.00-1.866Positive NewsEarnings ReportAnalyst ForecastAnalyst RevisionATRAAtara Biotherapeutics4.0803 of 5 stars$6.47-11.0%$17.75+174.3%-60.2%$38.57M$128.94M-0.25330News CoverageEarnings ReportPRLDPrelude Therapeutics3.0402 of 5 stars$0.88+13.0%$4.00+353.2%-77.7%$38.50M$7M-0.50120XLOXilio Therapeutics2.6391 of 5 stars$0.73+3.0%$4.00+447.2%-30.4%$37.85M$6.34M-0.4370Analyst UpgradeHigh Trading VolumeSCYXSCYNEXIS1.2992 of 5 stars$0.97+2.8%N/A-71.1%$37.75M$3.75M-1.3160Positive NewsEarnings ReportGap UpACRVAcrivon Therapeutics3.1856 of 5 stars$1.20+3.4%$19.17+1,497.2%-86.0%$37.63MN/A-0.4458Analyst RevisionGap UpHigh Trading Volume Related Companies and Tools Related Companies FBRX Competitors PLUR Competitors RNTX Competitors ATHE Competitors RNXT Competitors ATRA Competitors PRLD Competitors XLO Competitors SCYX Competitors ACRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCN Stock Free CYCN Stock Alerts